High-Dose Oral Medroxyprogesterone Acetate or Tamoxifen as Adjuvant Hormone Therapy for Node-Negative Early-Stage Breast Cancer: Randomized Trial with 7-Year Update

2004 ◽  
Vol 5 (2) ◽  
pp. 136-141 ◽  
Author(s):  
Christian Focan ◽  
Marc Beauduin ◽  
Françoise Majois ◽  
Jean-Luc Canon ◽  
Giuseppe Cusumano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Randomized Trial ◽  
Hormone Therapy ◽  
Medroxyprogesterone Acetate ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
High Dose ◽  
Adjuvant Hormone Therapy ◽  
Node Negative ◽  
Dose Oral

Early-stage breast cancer patients reporting difficulty sleeping, mood issues, or pain are more likely to refuse adjuvant hormone therapy.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12065-e12065
Author(s):  
Christian A. Thomas
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Hormone Therapy ◽  
Cancer Patients ◽  
Adjuvant Treatment ◽  
Early Stage ◽  
Stage I ◽  
Early Stage Breast Cancer ◽  
Breast Cancer Patients ◽  
Adjuvant Hormone Therapy

e12065 Background: Adjuvant hormone therapy is a crucial part of the treatment for patients with early stage breast cancer and an important quality measure for programs such as QOPI and the oncology care model (OCM). However, it is not known which factors influence some patients with early stage breast cancer to decline adjuvant hormone therapy. We hypothesized that specific self-reported symptoms might impact a patient’s decision to accept or decline adjuvant hormone therapy. Methods: Patients with stage 0 or I breast cancer were identified by chart review from 2011-2016 and de-identified. On the day patients received a recommendation for adjuvant treatment the following patient reported outcome measures (PROs) were analyzed: difficulty sleeping (DS), fatigue (F), mood (M such as anxiety and depression), and pain (P) on a 0-4 symptom scale based on CTCAE v. 4. PROs were then linked with a patient’s decision to accept or decline adjuvant therapy. Results: A total of 287 patients with stage 0 (n = 80) or stage I (n = 207) breast cancer were identified. 38 stage O and 103 stage I patients had evaluable PROs on the same day a recommendation for adjuvant hormone therapy was made. Overall 18/38 (47.4%) of stage 0 patients and 90 of 103 (87.4%) of stage I patients accepted adjuvant treatment. Stage 0 patients declining adjuvant therapy reported any grade of PROs: DS (40%, n = 8), F (35%, n = 7), M (35%, n = 7), P (20%, n = 4). Stage 0 patients accepting treatment reported: DS (22%, n = 4), F (44%, n = 8), M (6%, n = 1), P (20%, n = 4). Stage I patients who declined treatment reported: DS (54%, n = 7), F (46%, n = 6), M (38%, n = 5), P (62%, n = 8). Stage I patients accepting treatment reported: DS (41%, n = 37), F (49%, n = 44), M (31%, n = 28), P (36%, n = 32). Conclusions: Early stage breast cancer patients declining adjuvant hormone therapy are more likely to self report symptoms such as difficulty sleeping, mood disturbances (anxiety, depression), and pain than those accepting treatment.

Interstitial High Dose Rate (HDR) Brachytherapy for Early Stage Breast Cancer: A Report of 136 Cases

2007 ◽  
Vol 69 (3) ◽  
pp. S229 ◽  
Author(s):  
P.J. Anderson ◽  
R.J. Mark ◽  
R.S. Akins ◽  
T.R. Neumann ◽  
S. Gurley ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dose Rate ◽  
Early Stage ◽  
High Dose Rate ◽  
Early Stage Breast Cancer ◽  
High Dose ◽  
Hdr Brachytherapy

MDM2 amplification is an independent prognostic feature of node-negative, estrogen receptor-positive early-stage breast cancer

2011 ◽  
Vol 8 (2) ◽  
pp. 53-60 ◽  
Author(s):  
Matthias Choschzick ◽  
Uwe Heilenkötter ◽  
Annette Lebeau ◽  
Fritz Jaenicke ◽  
Luigi Terracciano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Node Negative ◽  
Estrogen Receptor Positive ◽  
Prognostic Feature ◽  
Mdm2 Amplification
Sign in / Sign up

Export Citation Format

Share Document